stockrowargenex SE
ARGX Healthcare Biotechnology
argenex SE’s revenue for fiscal 2025 (year ended December 2025) was $4.2 billion, up 88.6% from fiscal 2024.
- Revenue
- +52.1%
- EPS
- +43.9%
- Free cash flow
- +537.5%
Quarter to September 2026, against a year earlier
Follow ARGX
Alert me
argenex SE (ARGX) Net income
argenex SE's net income for fiscal 2025 was $1.1B, compared with −$21.7M in fiscal 2024. Over the twelve months to 30 June 2026 it was $1.6B. Over the past ten years it has ranged from −$720.3M (fiscal 2022) to $1.1B (fiscal 2025) — the current reading is the highest in ten years. Net income has risen for 3 consecutive fiscal years. argenex SE ranks 4th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $1.1B | — |
| FY2024 | −$21.7M | — |
| FY2023 | −$425.0M | — |
| FY2022 | −$720.3M | — |
| FY2021 | −$348.7M | — |
| FY2020 | −$477.6M | — |
| FY2019 | −$200.0M | — |
| FY2018 | −$96.7M | — |
| FY2017 | −$25.9M | — |
| FY2016 | −$23.7M | — |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| REGN Regeneron Pharmaceuticals, Inc. compare | $4.8B |
| ARGX argenex SE | $1.6B |
| RPRX Royalty Pharma PLC compare | $1.3B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $915.6M |
| GMAB Genmab A/S Sponsored ADR compare | $906.0M |
| INCY Incyte Corporation compare | $403.4M |
| ROIV Roivant Sciences Ltd. compare | −$414.6M |
| RVMD Revolution Medicines, Inc. compare | −$1.9B |
| MRNA Moderna, Inc. compare | −$3.2B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on ARGX
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement